Liberty Dialysis Brenham Llc is a medicare approved dialysis facility center in Brenham, Texas and it has 12 dialysis stations. It is located in Washington county at 604 Medical Courts, Brenham, TX, 77833. You can reach out to the office of Liberty Dialysis Brenham Llc at (979) 353-4440. This dialysis clinic is managed and/or owned by Fresenius Medical Care. Liberty Dialysis Brenham Llc has the following ownership type - Profit. It was first certified by medicare in June, 2009. The medicare id for this facility is 672601 and it accepts patients under medicare ESRD program.
| Name | Liberty Dialysis Brenham Llc |
|---|---|
| Location | 604 Medical Courts, Brenham, Texas |
| No. of Dialysis Stations | 12 |
| Medicare ID | 672601 |
| Managed By | Fresenius Medical Care |
| Ownership Type | Profit |
| Late Shifts | No |
| 604 Medical Courts, Brenham, Texas, 77833 | |
| (979) 353-4440 | |
| Not Available |
News Archive
When aggressive, malignant tumors appear in more than one location in the brain, patient survival tends to be significantly shorter than when the disease starts as a single tumor, even though patients in both groups undergo virtually identical treatments, according to research at Cedars-Sinai Medical Center's Maxine Dunitz Neurosurgical Research Institute.
Synergy Pharmaceuticals, Inc., a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, today announced that the next clinical trial of plecanatide to treat chronic idiopathic constipation patients, planned to begin in the second quarter of 2011, has been designed as a Phase II/III trial.
KineMed, Inc. today announced a non-exclusive research collaboration with Pfizer Inc. for the advancement of novel approaches towards metabolic disease, in particular Type II Diabetes.
Alere Inc., a global leader in enabling individuals to take charge of their health at home through the merger of rapid diagnostics and health management, today announced its financial results for the quarter ended March 31, 2012.
Molecular Dynamics will present its revolutionary whole body CZT digital SPECT/CT solution at the upcoming 101st Scientific Assembly and Annual Meeting of the Radiological Society of North America taking place in Chicago on Nov-29th through Dec-4th, in Booth 1122, Hall A.
› Verified 2 days ago
| NPI Number | 1407039688 |
| Doing Business As | Liberty Dialysis - Brenham Llc |
| Address | 604 Medical Courts Brenham, Texas, 77833 |
| Phone Number | (206) 236-5001 |
News Archive
When aggressive, malignant tumors appear in more than one location in the brain, patient survival tends to be significantly shorter than when the disease starts as a single tumor, even though patients in both groups undergo virtually identical treatments, according to research at Cedars-Sinai Medical Center's Maxine Dunitz Neurosurgical Research Institute.
Synergy Pharmaceuticals, Inc., a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, today announced that the next clinical trial of plecanatide to treat chronic idiopathic constipation patients, planned to begin in the second quarter of 2011, has been designed as a Phase II/III trial.
KineMed, Inc. today announced a non-exclusive research collaboration with Pfizer Inc. for the advancement of novel approaches towards metabolic disease, in particular Type II Diabetes.
Alere Inc., a global leader in enabling individuals to take charge of their health at home through the merger of rapid diagnostics and health management, today announced its financial results for the quarter ended March 31, 2012.
Molecular Dynamics will present its revolutionary whole body CZT digital SPECT/CT solution at the upcoming 101st Scientific Assembly and Annual Meeting of the Radiological Society of North America taking place in Chicago on Nov-29th through Dec-4th, in Booth 1122, Hall A.
› Verified 2 days ago
| Dialysis patients with Hemoglobin data | 46 |
News Archive
When aggressive, malignant tumors appear in more than one location in the brain, patient survival tends to be significantly shorter than when the disease starts as a single tumor, even though patients in both groups undergo virtually identical treatments, according to research at Cedars-Sinai Medical Center's Maxine Dunitz Neurosurgical Research Institute.
Synergy Pharmaceuticals, Inc., a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, today announced that the next clinical trial of plecanatide to treat chronic idiopathic constipation patients, planned to begin in the second quarter of 2011, has been designed as a Phase II/III trial.
KineMed, Inc. today announced a non-exclusive research collaboration with Pfizer Inc. for the advancement of novel approaches towards metabolic disease, in particular Type II Diabetes.
Alere Inc., a global leader in enabling individuals to take charge of their health at home through the merger of rapid diagnostics and health management, today announced its financial results for the quarter ended March 31, 2012.
Molecular Dynamics will present its revolutionary whole body CZT digital SPECT/CT solution at the upcoming 101st Scientific Assembly and Annual Meeting of the Radiological Society of North America taking place in Chicago on Nov-29th through Dec-4th, in Booth 1122, Hall A.
› Verified 2 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 47 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 454 |
| Percentage of adult patients getting regular hemodialysis at the center | |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
When aggressive, malignant tumors appear in more than one location in the brain, patient survival tends to be significantly shorter than when the disease starts as a single tumor, even though patients in both groups undergo virtually identical treatments, according to research at Cedars-Sinai Medical Center's Maxine Dunitz Neurosurgical Research Institute.
Synergy Pharmaceuticals, Inc., a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, today announced that the next clinical trial of plecanatide to treat chronic idiopathic constipation patients, planned to begin in the second quarter of 2011, has been designed as a Phase II/III trial.
KineMed, Inc. today announced a non-exclusive research collaboration with Pfizer Inc. for the advancement of novel approaches towards metabolic disease, in particular Type II Diabetes.
Alere Inc., a global leader in enabling individuals to take charge of their health at home through the merger of rapid diagnostics and health management, today announced its financial results for the quarter ended March 31, 2012.
Molecular Dynamics will present its revolutionary whole body CZT digital SPECT/CT solution at the upcoming 101st Scientific Assembly and Annual Meeting of the Radiological Society of North America taking place in Chicago on Nov-29th through Dec-4th, in Booth 1122, Hall A.
› Verified 2 days ago
| Adult patients getting regular peritoneal dialysis at the center | 30 |
| Adult patient months included in Kt/V greater than or equal to 1.7 | 233 |
| Percentage of adult patients getting regular peritoneal dialysis at the center | |
| Percentage of pediatric patients getting regular peritoneal dialysis at the center |
News Archive
When aggressive, malignant tumors appear in more than one location in the brain, patient survival tends to be significantly shorter than when the disease starts as a single tumor, even though patients in both groups undergo virtually identical treatments, according to research at Cedars-Sinai Medical Center's Maxine Dunitz Neurosurgical Research Institute.
Synergy Pharmaceuticals, Inc., a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, today announced that the next clinical trial of plecanatide to treat chronic idiopathic constipation patients, planned to begin in the second quarter of 2011, has been designed as a Phase II/III trial.
KineMed, Inc. today announced a non-exclusive research collaboration with Pfizer Inc. for the advancement of novel approaches towards metabolic disease, in particular Type II Diabetes.
Alere Inc., a global leader in enabling individuals to take charge of their health at home through the merger of rapid diagnostics and health management, today announced its financial results for the quarter ended March 31, 2012.
Molecular Dynamics will present its revolutionary whole body CZT digital SPECT/CT solution at the upcoming 101st Scientific Assembly and Annual Meeting of the Radiological Society of North America taking place in Chicago on Nov-29th through Dec-4th, in Booth 1122, Hall A.
› Verified 2 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Liberty Dialysis Brenham Llc with elevated calcium levels.
| Patients with hypercalcemia | 80 |
| Hypercalcemia patient months | 783 |
| Hypercalcemia patients with serumcalcium greater than 10.2 mg | |
| Patients with Serumphosphor | 83 |
| Patients with Serumphosphor less than 3.5 mg/dL | |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | |
| Patients with Serumphosphor greater than 7 mg/dL |
News Archive
When aggressive, malignant tumors appear in more than one location in the brain, patient survival tends to be significantly shorter than when the disease starts as a single tumor, even though patients in both groups undergo virtually identical treatments, according to research at Cedars-Sinai Medical Center's Maxine Dunitz Neurosurgical Research Institute.
Synergy Pharmaceuticals, Inc., a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, today announced that the next clinical trial of plecanatide to treat chronic idiopathic constipation patients, planned to begin in the second quarter of 2011, has been designed as a Phase II/III trial.
KineMed, Inc. today announced a non-exclusive research collaboration with Pfizer Inc. for the advancement of novel approaches towards metabolic disease, in particular Type II Diabetes.
Alere Inc., a global leader in enabling individuals to take charge of their health at home through the merger of rapid diagnostics and health management, today announced its financial results for the quarter ended March 31, 2012.
Molecular Dynamics will present its revolutionary whole body CZT digital SPECT/CT solution at the upcoming 101st Scientific Assembly and Annual Meeting of the Radiological Society of North America taking place in Chicago on Nov-29th through Dec-4th, in Booth 1122, Hall A.
› Verified 2 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 51 |
| Patient months included in arterial venous fistula and catheter summaries | 453 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer |
News Archive
When aggressive, malignant tumors appear in more than one location in the brain, patient survival tends to be significantly shorter than when the disease starts as a single tumor, even though patients in both groups undergo virtually identical treatments, according to research at Cedars-Sinai Medical Center's Maxine Dunitz Neurosurgical Research Institute.
Synergy Pharmaceuticals, Inc., a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, today announced that the next clinical trial of plecanatide to treat chronic idiopathic constipation patients, planned to begin in the second quarter of 2011, has been designed as a Phase II/III trial.
KineMed, Inc. today announced a non-exclusive research collaboration with Pfizer Inc. for the advancement of novel approaches towards metabolic disease, in particular Type II Diabetes.
Alere Inc., a global leader in enabling individuals to take charge of their health at home through the merger of rapid diagnostics and health management, today announced its financial results for the quarter ended March 31, 2012.
Molecular Dynamics will present its revolutionary whole body CZT digital SPECT/CT solution at the upcoming 101st Scientific Assembly and Annual Meeting of the Radiological Society of North America taking place in Chicago on Nov-29th through Dec-4th, in Booth 1122, Hall A.
› Verified 2 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | |
| Hospitalization Rate in facility | (Not Available) |
| Hospitalization Rate: Upper Confidence Limit | |
| Hospitalization Rate: Lower Confidence Limit |
News Archive
When aggressive, malignant tumors appear in more than one location in the brain, patient survival tends to be significantly shorter than when the disease starts as a single tumor, even though patients in both groups undergo virtually identical treatments, according to research at Cedars-Sinai Medical Center's Maxine Dunitz Neurosurgical Research Institute.
Synergy Pharmaceuticals, Inc., a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, today announced that the next clinical trial of plecanatide to treat chronic idiopathic constipation patients, planned to begin in the second quarter of 2011, has been designed as a Phase II/III trial.
KineMed, Inc. today announced a non-exclusive research collaboration with Pfizer Inc. for the advancement of novel approaches towards metabolic disease, in particular Type II Diabetes.
Alere Inc., a global leader in enabling individuals to take charge of their health at home through the merger of rapid diagnostics and health management, today announced its financial results for the quarter ended March 31, 2012.
Molecular Dynamics will present its revolutionary whole body CZT digital SPECT/CT solution at the upcoming 101st Scientific Assembly and Annual Meeting of the Radiological Society of North America taking place in Chicago on Nov-29th through Dec-4th, in Booth 1122, Hall A.
› Verified 2 days ago